InVivo Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

invivotherapeutics.com

Stage

PIPE | IPO

Market Cap

0.01B

Stock Price

3.94

About InVivo Therapeutics

InVivo Therapeutics (NASDAQ: NVIV) develops and commercializes technologies for the treatment of spinal cord injuries (SCI).

InVivo Therapeutics Headquarter Location

One Kendall Square Building 1400 East, Floor 4

Cambridge, Massachusetts, 02139,

United States

617-863-5500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing InVivo Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

InVivo Therapeutics is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

InVivo Therapeutics Patents

InVivo Therapeutics has filed 11 patents.

The 3 most popular patent topics include:

  • Biomaterials
  • Biotechnology
  • Dosage forms
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/13/2012

11/20/2018

Polymers, Polymer chemistry, Copolymers, Thermoplastics, Polymerization reactions

Grant

Application Date

7/13/2012

Grant Date

11/20/2018

Title

Related Topics

Polymers, Polymer chemistry, Copolymers, Thermoplastics, Polymerization reactions

Status

Grant

Latest InVivo Therapeutics News

InVivo Therapeutics Announces Reverse Stock Split

Apr 14, 2022

03/07 04/14/2022 | 09:31pm BST Message : *Required fields InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. The company anticipates the reverse stock split will become effective at 5:00 p.m. Eastern Time on April 26, 2022, and shares of InVivo Therapeutics common stock will trade on a post-split basis under the company's existing trading symbol, “NVIV,” at the market open on April 27, 2022. The new CUSIP number for the company’s common stock following the reverse stock split will be CUSIP 46186M 605/ISIN US46186M6057. At the effective time of the reverse stock split, every 25 shares of InVivo Therapeutics common stock will be combined into 1 share of InVivo Therapeutics common stock. In connection with the reverse stock split, the authorized shares will be reduced from 50 million shares to 2 million shares. The reverse stock split is anticipated to reduce the company’s issued and outstanding shares of common stock from approximately 34.3 million to approximately 1.4 million. Fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share, and all shares of common stock (including fractions thereof) issuable upon the reverse stock split to a given stockholder shall be aggregated for the purpose of determining whether the reverse stock split would result in the issuance of a fractional share. In addition, proportionate adjustments will be made to the exercise prices of the company’s outstanding stock options and warrants and to the number of shares issued and issuable under the company’s existing stock incentive plans. The implementation of the reverse stock split is intended to increase the per share trading price of the company’s common stock to fulfill the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com . Safe Harbor Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect” and similar expressions, and include statements regarding the company’s planned reverse stock split and statements regarding the company’s continued listing on the Nasdaq Capital Market. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to: the company’s ability to effect the 1-for-25 reverse stock split and the administrative process related thereto, and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and its other filings with the SEC, including the company’s quarterly reports on Form 10-Q and current reports on Form 8-K. The company does not undertake to update these forward-looking statements. View source version on businesswire.com: https://www.businesswire.com/news/home/20220414005611/en/ © Business Wire 2022

InVivo Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

InVivo Therapeutics Rank

You May Also Like

M
Matricelf

Matricelf's technology enables the production of autologous engineered tissue composed of scaffold and cells derived from patients' biopsies.

Lineage Cell Therapeutics Logo
Lineage Cell Therapeutics

Lineage Cell Therapeutics (NYSE American and TASE: LCTX) is a clinical-stage biotechnology company developing cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.